academic article

• Lau DKMouradov DWasenang WLuk IYScott CMWilliams DSYeung YHLimpaiboon TIatropoulos GFJenkins LJReehorst CMChionh FNikfarjam MCroagh DDhillon ASWeickhardt AJMuramatsu TSaito YTebbutt NCSieber OMMariadason JM. Genomic profiling of biliary tract cancer cell lines reveals molecular subtypes and actionable drug targets.  iScience.  21:624-637. 2019
  Full text if available
• Lau DKTay RYYeung YHChionh FMooi JMurone CSkrinos EPrice TJMariadason JMTebbutt NC. Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.  British Journal of Cancer.  118:966-971. 2018
  Full text if available
• Yeung YLau DKChionh FTran HTse JWTWeickhardt AJNikfarjam MScott AMTebbutt NCMariadason JM. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.  Molecular Oncology.  11:1130-1142. 2017
  Full text if available
• Chionh FLau DYeung YPrice TTebbutt N. Oral versus intravenous fluoropyrimidines for colorectal cancer.  Cochrane Database of Systematic Reviews.  2017:1-218. 2017
  Full text if available
• Parakh SMurphy CLau DCebon JSAndrews MC. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.  Journal of Clinical Pharmacy and Therapeutics.  40:121-123. 2015
  Full text if available
• Lau DKAndrews MCTurner NAzad AADavis IDCebon JS. A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.  Melanoma Research: an international journal of rapid communications of basic and clinical research in melanoma.  24:144-149. 2014
  Full text if available